返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® OrthoRecon Project Listed in National Key R&D Plan

[2017-06-19] 

Beijing, China – On June 1, the project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System," co-launched by Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort®OrthoRecon"), was listed in the National Key Research & Development ("R&D") Plan, falling into the category of "Digital Diagnostic Equipment R&D," according to the announcement regarding the arrangement of five key categories (including Stem Cells and Translational Research) of the National Key R&D Plan for the Year 2017 released on the official website of the China National Center for Biotechnology Development under the Ministry of Science and Technology.
 
Aiming to seize the opportunity of the new round of revolution in the healthcare industry, the category of "Digital Diagnostic Equipment R&D" is being oriented on early diagnosis, accurate diagnosis, minimally invasive treatment, precise treatment, while focused on 10 key strategic products such as multimodal molecular imaging and large-scale radiotherapy equipment. It is expected to systematically strengthen the key technology research, push the development of cutting-edge technologies, facilitate the improvement of detecting technique, standardized systems, application solution and pilot application evaluation research, and thereby to speed up the integration of the production and innovation of China's medical device industry and help China's digital diagnostic equipment industry ascend into the international advanced level. The project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System" is a four-year project co-developed by MicroPort®OrthoRecon, Shanghai Ninth People's Hospital of Shanghai Jiaotong University, Peking University, Beijing Institute of Technology, Third Military Medical University, Fudan University, and Shanghai Medical Device Testing Institute.
 
The National Key R&D Plan merges several prominent state sci-tech programs, including the program 863 and program 973, National Key Technology Support Program, International Scientific and Technological Cooperation Program of China, Industrial Technology Research and Development Fund, and Scientific Research Fund of Public Service Industry. The plan focuses on research in fields vital to the country's development and people's well-being, such as agriculture, energy, the environment and health, as well as strategic fields key to industrial competitiveness, innovation and national security. The five key categories mentioned in the announcement includes Stem Cells and Translational Research, Digital Diagnostic Equipment R&D, Prevention and Control of Major Chronic Non-Infectious Diseases, Biosafety Key Technology R&D, Biomedical Materials R&D & Tissue and Organ Repair and Replacement. The five key categories received a total of 782 applications and 167 of them eventually obtained government funding totaling at around 2.5 billion yuan.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® OrthoRecon Hosts SuperPath™ Training Course
[Next]:MicroPort® Attends OCC 2017